Fasciculation Clinical Trial
Official title:
Effects of Cisatracurium on Succinylcholine-induced Fasciculations and Myalgia
| Verified date | June 2015 |
| Source | Yangzhou No.1 People's Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | China: Ethics Committee |
| Study type | Interventional |
The purpose of this study is to investigate the effects of different doses of cisatracurium pretreatment on succinylcholine-induced fasciculations and postoperative myalgia.
| Status | Completed |
| Enrollment | 90 |
| Est. completion date | January 2014 |
| Est. primary completion date | January 2014 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 20 Years to 65 Years |
| Eligibility |
Inclusion Criteria: - American Standards Association (ASA) physical status I or II patients scheduled for elective laparoscopic cholecystectomies with tracheal intubation requiring general anesthesia - 20 - 65 years old - without acid-base imbalance and electrolyte disturbance - with normal hepatic and renal function Exclusion Criteria: - Patients with known hyperkalemia - Patients with increased intraocular pressure - Patients with increased intracranial pressure - Patients with symptoms of gastroesophageal reflux - Patients with anticipated airway difficulties - Patients with malignant fever - Patients with neuromuscular disease - Patients with burn or crush injuries - Patients with taking drugs known to alter the action of neuromuscular blockers - Patients with with a body mass index exceeding 30 |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Yangzhou No.1 People's Hospital |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The presence of fasciculations | After the injection of succinylcholine for 1.5 minutes | Yes | |
| Secondary | Side effects of the pretreatment of cisatracurium | At the time of three minutes after the pretreatment of cisatracurium | Yes | |
| Secondary | The time to maximal depression of twitch | From the time of 4.5 minutes after the pretreatment of cisatracurium for two minutes | Yes | |
| Secondary | The extent to maximal depression of twitch | From the time of 4.5 minutes after the pretreatment of cisatracurium for two minutes | Yes | |
| Secondary | The time for twitch recovery to 20% of its control value | From the time of 4.5 minutes after the pretreatment of cisatracurium for two minutes | Yes | |
| Secondary | The grades of endotracheal intubation | At intubating time | Yes | |
| Secondary | The changes of serum potassium | After entering the operating theater till the anesthesia induction, at intubating, and 5 min after intubation | Yes | |
| Secondary | Myalgia at 24 hours postoperatively | At 24 hours postoperatively | Yes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03338114 -
Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05760976 -
Median Effective Dose of Cisatracurium for the Prevention of Fasciculation Caused by the Injection of Succinylcholine
|
N/A | |
| Terminated |
NCT03334786 -
Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS
|
Phase 1/Phase 2 |